Leading the Mission to Prevent and Reverse Blindness
Worldwide, 285 million people are visually impaired and 39 million are blind. Penn Ophthalmology is a preeminent medical research center at the forefront of preventing and reversing visual impairment and blindness. In 2017, Penn Ophthalmology pioneered the first gene therapy for a hereditary retinal disease to be approved by the FDA. This therapy has allowed patients born with blinding conditions to regain and maintain vision. Researchers at Penn are currently developing therapies for a range of other blinding disorders. Many of the Department's advances in vision-saving therapy have been made possible by donations from individuals and organizations.
Gifts can be made to specific funds through the following links:
General/Scheie Eye Teaching & Research Fund
Glaucoma Research Fund
Dry Eye Program Fund
Gifts by Check
Gifts by check, made payable to the Scheie Eye Institute, can be mailed to:
Penn Medicine Development & Alumni Relations
Attn: Mary Tong
3535 Market Street, Suite 750
Philadelphia, PA 19104
To learn more, contact Mary Tong at 215.746.2204 or firstname.lastname@example.org.